171 related articles for article (PubMed ID: 2192978)
1. Long-term treatment of acromegaly with octreotide (Sandostatin).
Page MD; Millward ME; Hourihan M; Hall R; Scanlon NF
Horm Res; 1990; 33 Suppl 1():20-30; discussion 30-1. PubMed ID: 2192978
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
Ho KY; Weissberger AJ; Marbach P; Lazarus L
Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
[TBL] [Abstract][Full Text] [Related]
3. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
[TBL] [Abstract][Full Text] [Related]
4. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
[TBL] [Abstract][Full Text] [Related]
7. Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group.
Arosio M; Macchelli S; Rossi CM; Casati G; Biella O; Faglia G
Eur J Endocrinol; 1995 Oct; 133(4):430-9. PubMed ID: 7581966
[TBL] [Abstract][Full Text] [Related]
8. Administration of high-dose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly.
White MC; James RA; Chatterjee S; Mother M; Hall K; Dunne MJ; Baister ER; Kendall-Taylor P
Horm Res; 1990; 33 Suppl 1():13-8; discussion 18-9. PubMed ID: 1972690
[TBL] [Abstract][Full Text] [Related]
9. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
10. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
Davies PH; Stewart SE; Lancranjan L; Sheppard MC; Stewart PM
Clin Endocrinol (Oxf); 1998 Mar; 48(3):311-6. PubMed ID: 9578821
[TBL] [Abstract][Full Text] [Related]
11. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
12. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
Ezzat S; Redelmeier DA; Gnehm M; Harris AG
J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
Shi YF; Harris AG; Zhu XF; Deng JY
Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
[TBL] [Abstract][Full Text] [Related]
14. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.
Lindsay JR; McConnell EM; Hunter SJ; McCance DR; Sheridan B; Atkinson AB
Pituitary; 2004; 7(3):139-144. PubMed ID: 16328564
[TBL] [Abstract][Full Text] [Related]
15. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly.
Stewart PM; Kane KF; Stewart SE; Lancranjan I; Sheppard MC
J Clin Endocrinol Metab; 1995 Nov; 80(11):3267-72. PubMed ID: 7593436
[TBL] [Abstract][Full Text] [Related]
16. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
Plöckinger U; Liehr RM; Quabbe HJ
J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
[TBL] [Abstract][Full Text] [Related]
17. Sandostatin LAR in acromegalic patients: a dose-range study.
Fløgstad AK; Halse J; Haldorsen T; Lancranjan I; Marbach P; Bruns C; Jervell J
J Clin Endocrinol Metab; 1995 Dec; 80(12):3601-7. PubMed ID: 8530606
[TBL] [Abstract][Full Text] [Related]
18. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.
McKnight JA; McCance DR; Sheridan B; McIlrath E; Hadden DR; Kennedy L; Atkinson AB
Clin Endocrinol (Oxf); 1991 Feb; 34(2):119-25. PubMed ID: 1902408
[TBL] [Abstract][Full Text] [Related]
19. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.
Freda PU; Reyes CM; Conwell IM; Sundeen RE; Wardlaw SL
J Clin Endocrinol Metab; 2003 May; 88(5):2037-44. PubMed ID: 12727951
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
Vance ML; Harris AG
Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
